XORTX Therapeutics Inc. (XRTX) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -416.98%, forward earnings yield 185.19%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.7 | -0.03 | -2.29 | 0.00 | - |
| 2017 | -1.7 | 0.44 | -1.24 | 0.00 | - |
| 2018 | -0.4 | 0.00 | 5.15 | 0.00 | - |
| 2019 | -3.6 | 0.04 | -10.59 | 0.00 | - |
| 2020 | -1.8 | -0.03 | 1.84 | 0.00 | - |
| 2021 | -3.1 | 0.10 | 0.39 | 0.00 | - |
| 2022 | -0.4 | 0.00 | 0.42 | 0.00 | - |
| 2023 | -0.3 | 0.00 | 0.19 | 0.00 | - |
| 2024 | -0.2 | -0.02 | 0.19 | 0.00 | - |
| 2025 | -0.2 | 0.00 | 0.26 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.05 | $0.00 | $-414.83K | - |
| 2017 | $-2.24 | $0.00 | $-474.2K | - |
| 2018 | $-6.45 | $0.00 | $-3.78M | - |
| 2019 | $-1.06 | $0.00 | $-629.58K | - |
| 2020 | $-1.73 | $0.00 | $-1.28M | - |
| 2021 | $-1.19 | $0.00 | $-1.3M | - |
| 2022 | $-4.72 | $0.00 | $-6.99M | - |
| 2023 | $-1.08 | $0.00 | $-2.15M | - |
| 2024 | $-7.90 | $0.00 | $-4.54M | - |
| 2025 | $-3.90 | $0.00 | $-3.71M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.35 | $-0.35 – $-0.35 | $3.25M | $3.25M – $3.25M | 1 |
| 2027 | $0.80 | $0.80 – $0.80 | $16M | $16M – $16M | 1 |
